# Zealand Pharma (ZLDPF) 宣布發表其第二期 ZUPREME-1 試驗中評估實驗性藥物 petrelintide 的額外數據。

*biotech · news · 2026-06-05 · Markets Insider*

## Key points

- Petrelintide 在 42 週時達到平均體重減輕最高 10.7%，而安慰劑為 1.7%。
- 88% 至 98% 的參與者成功提升至 petrelintide 的目標維持劑量。
- Petrelintide 改善主要心血管風險因子，減少腰圍、高敏感性 C 反應蛋白（hs-CRP）及三酸甘油脂。
- 僅有 1.5% 的 petrelintide 參與者因腸胃事件停止用藥，且無意外安全性發現。

Zealand Pharma (ZLDPF) announced the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes Association, taking place in New Orleans, Louisiana. Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo. Treatment with petrelintide was associated with improvements in cardiometabolic disease risk factors and was well tolerated with rates of gastrointestinal-related adverse events generally similar to placebo. Petrelintide led to mean reductions in body weight from baseline to Week 42 of up to 10.7% vs 1.7% for placebo. In total, 88%-98% of participants successfully escalated to their targeted maintenance dose of petrelintide. Most GI adverse events were mild. Nausea was the most common GI AE, reported for 19.6% of participants on petrelintide vs 6.2% on placebo. Vomiting was rare with petrelintide, while the rates of diarrhea and constipation were similarly low for petrelintide and placebo. Only 1.5% of participants discontinued petrelintide due to gastrointestinal adverse events, and there were no unexpected safety findings. Petrelintide was associated with meaningful improvements in key cardiovascular risk factors, with the reductions with petrelintide ranging from 7.9-10.8cm for waist circumference, 17%-41% for high-sensitivity C-reactive protein and 12%-21% for triglycerides. Claim 55% Off TipRanks

**Companies:** Zealand Pharma
**Countries:** United States

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/zealand-pharma-presents-additional-data-from-zupreme-1-trial-1036230001)

---

Canonical: https://newsio.io/zh-TW/n/1c01262a-92be-4c46-985a-387b009df393/zealand-pharma-zldpf-zupreme-1-petrelintide
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works